A vaccine up to 89 percent effective against new strains of coronavirus is expected to be launched in India by June 2021. Serum Institute of India (SII) CEO Adar Poonawalla said on Saturday that his company has applied to start another Covid-19 vaccine trial in partnership with Novavax Inc in India. He said that the company can launch ‘Covovax’ by June 2021. Novavax also claimed that its vaccine was found to be effective in developing immunity against new strains of the virus spreading in Britain and South Africa. Serum Institute of India (SII) is already producing the ‘Covishield’ vaccine, developed by Oxford University and the British-Swedish company AstraZeneca. The Central Government has purchased 10 million doses of the vaccine for the ongoing vaccination campaign in the country.